Clinical Trials

Accrual Status
Limit to SWOG Trials

1027 Results

Active Filters

    Open
    Phase
    Accrual
    0%
    SWOG Clinical Trial Number
    S1900K

    A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

    Status Notes
    S1900K will open to accrual December 18, 2023, effective 3:00 p.m. EST.
    Research Committee(s)
    LungMAP
    Activated
    12-18-2023
    ClinicalTrials.gov Registry Number
    NCT06031688
    Open
    Phase
    Accrual
    0%
    SWOG Clinical Trial Number
    S2213

    A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

    Status Notes
    S2213 is open to patient accrual December 01, 2023, effective 12:00 p.m. Pacific Time.
    Research Committee(s)
    Myeloma
    Activated
    12-01-2023
    ClinicalTrials.gov Registry Number
    06022939
    Open
    Phase
    Accrual
    1%
    SWOG Clinical Trial Number
    S2206

    A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer

    Status Notes
    This study is open to patient accrual effective 10/30/23.
    Research Committee(s)
    Breast Cancer
    Symptom Control and Quality of Life
    Activated
    10-30-2023
    ClinicalTrials.gov Registry Number
    06058377
    Open
    Phase
    Accrual
    2%
    SWOG Clinical Trial Number
    S2210

    S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

    Status Notes
    Active as of 08/14/2023, 12 PM PST.
    Research Committee(s)
    Genitourinary Cancer
    Activated
    08-14-2023
    ClinicalTrials.gov Registry Number
    NCT05806515
    Open
    Phase
    Accrual
    4%
    SWOG Clinical Trial Number
    S2212

    TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)

    Status Notes
    This study is active in SWOG as of July 21, 2023.
    Research Committee(s)
    Breast Cancer
    Activated
    07-21-2023
    ClinicalTrials.gov Registry Number
    NCT05929768
    Open
    Phase
    Accrual
    4%
    SWOG Clinical Trial Number
    S2207

    Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma

    Status Notes
    S2207 will open to accrual June 30, 2023, effective 3:00 p.m. EST.
    Research Committee(s)
    Lymphoma
    Activated
    06-30-2023
    ClinicalTrials.gov Registry Number
    05890352